Bernstein
Bernstein: Amgen’s third-quarter results beat expectations, but growth quality and expense timing differ
Amgen’s growth products offset some declines in older drugs, and the company raised its full-year revenue and earnings-per-share guidance; Bernstein believes one-time sales benefits and expense timing also boosted third-quarter performance.